MCRPCの被験者におけるアカパタマブの安全性、忍容性、薬物動態、および有効性
転移性去勢抵抗性前立腺癌患者における前立腺特異的膜抗原半減期の延長された二重特異性 T 細胞エンゲージャー Acapatamab の安全性、忍容性、薬物動態、および有効性を評価する第 1 相試験
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant prostate cancer, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
調査の概要
状態
詳細な説明
This is a phase I, first-in-human study to evaluate the safety and tolerability of acapatamab; a half-life extended (HLE) bispecific T-cell engager (BiTE®) construct, alone and in combination with pembrolizumab, etanercept prophylaxis and cytochrome P450 (CYP) phenotyping cocktail in subjects with metastatic castration-resistant prostate cancer.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
Campbell、California、アメリカ、95008
- El Camino Hospital
-
Duarte、California、アメリカ、91010
- City of Hope National Medical Center
-
Long Beach、California、アメリカ、90813
- City of Hope at Long Beach Elm
-
Los Angeles、California、アメリカ、90095
- University of California Los Angeles
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Emory University
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa Hospitals and Clinics
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70112
- Tulane Medical Center
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- Washington University
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89169
- Comprehensive Cancer Centers of Nevada
-
-
New York
-
New York、New York、アメリカ、10065
- Weill Cornell Medical College
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- University of Texas Southwestern Medical Center
-
-
-
-
-
Rotterdam、オランダ、3015 GD
- Erasmus Medisch Centrum
-
-
-
-
New South Wales
-
Camperdown、New South Wales、オーストラリア、2050
- Chris OBrien Lifehouse
-
Randwick、New South Wales、オーストラリア、2031
- Scientia Clinical Research Ltd
-
-
Victoria
-
Parkville、Victoria、オーストラリア、3050
- Peter MacCallum Cancer Centre
-
-
-
-
-
Linz、オーストリア、4020
- Ordensklinikum Linz Elisabethinen
-
Salzburg、オーストリア、5020
- Landeskrankenhaus Salzburg
-
Vienna、オーストリア、1090
- Universitaetsklinikum Allgemeines Krankenhaus Wien
-
Vienna、オーストリア、1020
- Krankenhaus der Barmherzigen Brueder Wien
-
-
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 4E6
- BC Cancer Vancouver
-
-
-
-
-
Singapore、シンガポール、119074
- National University Hospital
-
Singapore、シンガポール、169610
- National Cancer Centre Singapore
-
-
-
-
-
Villejuif、フランス、94805
- Institut Gustave Roussy
-
-
-
-
-
Brussels、ベルギー、1200
- Universite Catholique de Louvain Cliniques Universitaires Saint Luc
-
Ghent、ベルギー、9000
- Universitair Ziekenhuis Gent
-
-
-
-
-
Taoyuan、台湾、33305
- Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation
-
-
-
-
Chiba
-
Kashiwa-shi、Chiba、日本、277-8577
- National Cancer Center Hospital East
-
-
Kanagawa
-
Yokohama、Kanagawa、日本、232-0024
- Yokohama City University Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
All Parts
Inclusion Criteria:
- Subject has provided informed consent prior to initiation of any study specific activities/procedures
- Subjects with histologically or cytologically confirmed mCRPC who are refractory to a novel antiandrogen therapy (abiraterone, enzalutamide, and/or apalutamide) and have failed at least 1 (but not more than 2) taxane regimens (or who are deemed medically unsuitable to be treated with a taxane regimen or have actively refused treatment with a taxane regimen). Progression on novel antiandrogen therapy may have occurred in the non-metastatic CRPC setting
- Subjects must have undergone bilateral orchiectomy or must be on continuous ADT with a gonadotropin releasing hormone (GnRH) agonist or antagonist
- Total serum testosterone </= 50 ng/dL or 1.7 nmol/L
- Evidence of progressive disease, defined as 1 or more PCWG3 criteria:
- PSA level >/= 1 ng/mL that has increased on at least 2 successive occasions at least 1 week apart
- nodal or visceral progression as defined by RECIST 1.1 with PCGW3 modifications
- appearance of 2 or more new lesions in bone scan
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1
- Life expectancy >/= 6months
Exclusion Criteria:
- Any anticancer therapy or immunotherapy within 4 weeks of start of first dose, not including luteinizing hormone-releasing hormone agonist (LHRH)/GnRH analogue (agonist/antagonist). Subjects on a stable bisophosphonate or denosumab regimen for >/= 30 days prior to randomization are eligible
- Prior PSMA-targeted therapy (subjects on prior therapy may be eligible if discussed with Amgen medical monitor prior to enrollment)
- Central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression
- Active autoimmune disease or any other diseases requiring immunosuppressive therapy while on study
- Needing chronic systemic corticosteroid therapy (prednisone > 10 mg per day or equivalent) or any other immunosuppressive therapies (including anti-tumor necrosis factor alpha [TNF alpha] therapies) unless stopped 7 days prior to start of first dose
- Myocardial infarction, unstable angina, cardiac arrhythmia requiring medication, and/or symptomatic congestive heart failure (New York Heart Association > class II) within 12 months of first dose of acapatamab
Part 2 only:
- Subjects on a prior PD-1 or PD-L1 inhibitor who experienced a Grade 3 or higher immune-related adverse event prior to first day of dosing
- History or evidence of interstitial lung disease or active, non-infectious pneumonitis
Part 3 only:
- Evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of investigational product
Part 6 only:
Subjects are excluded from this cohort if any of the following additional criteria apply:
- Subjects taking strong OAT3 inhibitors (eg, probenecid) or adjust the dosing to 1 mg PO QD.
- Subjects with latent or active tuberculosis at screening
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1 Dose-exploration: acapatamab treatment
Part 1 dose-exploration: acapatamab is administered intravenously. The dose-exploration phase of the study will estimate the MTD of acapatamab. RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an MTD. |
Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
他の名前:
|
|
実験的:Part 1 Dose-expansion: acapatamab treatment
Part 1 dose-expansion: acapatamab is administered intravenously at the MTD/RP2D. |
Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
他の名前:
|
|
実験的:Part 2: acapatamab + Pembrolizumab
Part 2: acapatamab is administered intravenously at the MTD/RP2D. Pembrolizumab will be administered intravenously. |
Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
他の名前:
Combined with acapatamab for investigational treatment of mCRPC
他の名前:
|
|
実験的:Part 3: acapatamab + Etanercept Prophylaxis
Part 3: acapatamab is administered intravenously at RP2D/MTD levels. Etanercept will be administered subcutaneously in cycle 1 only. |
Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
他の名前:
Prophylaxis for acapatamab-related cytokine release syndrome.
他の名前:
|
|
実験的:Part 4: acapatamab 24 Hour Monitoring
Part 4: acapatamab is administered intravenously at RP2D/MTD with 24-hour monitoring. |
Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
他の名前:
|
|
実験的:Part 5: acapatamab Outpatient Cohort
Part 5: acapatamab is administered intravenously at RP2D/MTD in an outpatient setting with 8-hour monitoring. |
Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
他の名前:
|
|
実験的:Part 6: acapatamab + Cytochrome P450 (CYP) Cocktail Drug Interaction
Part 6: acapatamab is administered intravenously at RP2D/MTD. A CYP phenotyping cocktail will be administered orally. |
Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
他の名前:
Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With a Dose Limiting Toxicity (DLT)- Parts 1 and 2
時間枠:Day 1 to 28 of Cycle 1 (length of cycle is 28 days)
|
DLTs are defined as any adverse event with an onset within first 28 days following first dose of AMG 160 monotherapy (Part 1) or in combination with pembrolizumab (Part 2) with any of the following criteria unless clearly attributable to causes other than AMG 160 treatment: • grade 5 toxicity (eg, death not due to disease progression) |
Day 1 to 28 of Cycle 1 (length of cycle is 28 days)
|
|
Number of Participants With Treatment Emergent Adverse Events- Parts 1, 2, 3, 4, and 5
時間枠:Up to 30 days after the last dose of study drug, or start of new anti-cancer therapy, whichever occurs first
|
A treatment-emergent adverse event is one that occurs on or after the first dose of study treatment and up to 30 days after the last dose. Adverse events were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests were recorded as adverse events. |
Up to 30 days after the last dose of study drug, or start of new anti-cancer therapy, whichever occurs first
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response (OR) Rate- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years
|
OR was defined as a partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, confirmed by a repeat assessment at least 4 weeks later. Participants who did not experience a PR/CR or did not have any follow-up tumor assessments were regarded as non-responders. |
Up to 3 years
|
|
Prostate-specific Antigen (PSA) Response- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years
|
A PSA response (PSA 30) is defined as a ≥ 30% reduction from the baseline PSA, (PSA 50) is defined as a ≥ 50% reduction from the baseline PSA, (PSA 70) is defined as a ≥ 70% reduction from the baseline PSA, and (PSA 90) is defined as a ≥ 90% reduction from the baseline PSA. PSA response must be confirmed by a second consecutive value ≥ 3 weeks later. |
Up to 3 years
|
|
Duration of Response (DOR)-RECIST 1.1- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years
|
DOR is defined as the time from the date of an initial objective response per RECIST 1.1 to the earlier of progression or death. Participants who had not ended their response at the time of analysis had DOR censored at their last evaluable tumor assessment. |
Up to 3 years
|
|
Duration of PSA Response- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years
|
PSA DOR is defined as the time from the date of an initial PSA response (PSA 50) to the earlier of PSA progression or death. Subjects who have not ended their response at the time of analysis will have PSA DOR censored on the date of their last PSA measurement. This endpoint only applies to subjects with a PSA response (PSA 50). |
Up to 3 years
|
|
Percentage of Participants With 68Gallium (68Ga)-Prostate-specific Membrane Antigen (PSMA) Response Parts 1, 2, and 3
時間枠:Up to 3 years
|
A Gallium PSMA-11 response is a ≥50% reduction from baseline in the maximum standardized uptake value (SUV) using 68Gallium (68Ga)-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT). |
Up to 3 years
|
|
Percentage of Participants With F-fluorodeoxyglucose (FDG) Response- Parts 1, 2, and 3
時間枠:Up to 3 years
|
A FDG PET response is a ≥50% reduction from baseline in the maximum SUV using 18F-FDG PET/CT. |
Up to 3 years
|
|
Time to Progression (Radiographic)- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years
|
Time to radiographic progression is defined as the time from study Day 1 until the first documentation of radiographic disease progression in the absence of subsequent anticancer therapy. Time to radiographic progression will be censored at the last evaluable post-baseline tumor assessment prior to subsequent anti-cancer therapy; otherwise, at study Day 1. |
Up to 3 years
|
|
Time to Progression (PSA)- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years
|
Time to PSA progression is defined as the interval from study Day 1 to PSA progression; otherwise, time to PSA progression is censored on the date of the last PSA measurement. If a participant has no baseline or no post-baseline PSA measurement, time to PSA progression will be censored at study Day 1. |
Up to 3 years
|
|
Progression Free Survival (Radiographic)- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years
|
Radiographic progression free survival (rPFS) is defined as the interval from study day 1 to the earlier of a radiographic progression or death from any cause; otherwise, rPFS is censored at the last evaluable tumor assessment date. If a subject has no post-baseline radiographic tumor assessment and a vital status of alive or unknown, rPFS will be censored at study day 1. |
Up to 3 years
|
|
Progression Free Survival (PSA)- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years
|
PSA PFS is defined as the interval from study day 1 to the earlier of a PSA progression or death from any cause; otherwise, PSA PFS is censored on the date of the last PSA measurement. If a subject has no baseline or no post-baseline PSA measurement and a vital status of alive or unknown, PSA PFS will be censored at study day 1. |
Up to 3 years
|
|
Overall Survival- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years
|
Overall survival (OS) is defined as the time from the date of study Day 1 until death due to any cause. |
Up to 3 years
|
|
Percentage of Participants With Circulating Tumor Cell Response (CTC0)- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years
|
CTC0 is defined as reduction of CTCs > 0 to 0 at any post-baseline measurement. CTC0 response is applicable only for participants with baseline CTC > 0. |
Up to 3 years
|
|
Percentage of Participants With CTC Conversion- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years
|
CTC conversion is defined as ≥ 5 CTCs/7.5 mL blood to ≤ 4 CTCs/7.5 mL blood at any post-baseline measurement. CTC conversion is applicable only for subjects with baseline CTC ≥ 5.. |
Up to 3 years
|
|
Time to Symptomatic Skeletal Events (SSE)- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years
|
Time to SSE is defined as time from study day 1 to the first SSE. Otherwise, SSE is censored at the last dose date of AMG 160 or pembrolizumab or end of safety follow up date, whichever is later. |
Up to 3 years
|
|
Maximum Observed Concentration (Cmax) of AMG 160 - Parts 1, 2, and 3
時間枠:Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
|
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of pharmacokinetic (PK) parameters. Concentrations below the lower limit of quantification (LLOQ) (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation. |
Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
|
|
Time to Cmax (Tmax) of AMG 160- Parts 1, 2, and 3
時間枠:Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 696 hours)
|
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. Actual time post dose was used for calculations. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation. |
Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 696 hours)
|
|
Minimum Serum Concentration (Cmin) of AMG 160- Parts 1, 2, and 3
時間枠:Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
|
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation. |
Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
|
|
Area Under the Concentration-time Curve (AUC) From Time 0 to Last Quantifiable Concentration (AUClast) of AMG 160- Parts 1, 2, and 3
時間枠:Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
|
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation. |
Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
|
|
AUC Over the Dosing Interval (AUCtau)- Parts 1, 2, and 3
時間枠:Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
|
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation. |
Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
|
|
Terminal Half-life (t1/2,z) of AMG 160- Parts 1, 2, and 3
時間枠:Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
|
Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis. PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation. |
Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:MD、Amgen
出版物と役立つリンク
一般刊行物
- Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan DSW, Wong A, Uemura H, Lemech C, Meran J, Yu Y, Minocha M, McComb M, Penny HL, Gupta V, Hu X, Jurida G, Kouros-Mehr H, Janat-Amsbury MM, Eggert T, Tran B. A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Apr 15;30(8):1488-1500. doi: 10.1158/1078-0432.CCR-23-2978.
- Hushmandi K, Einollahi B, Lee EHC, Sakaizawa R, Glaviano A, Reiter RJ, Saadat SH, Farani MR, Huh YS, Aref AR, Salimimoghadam S, Kumar AP. Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence. Int J Biol Sci. 2025 Jan 27;21(4):1410-1435. doi: 10.7150/ijbs.96155. eCollection 2025.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 傷やけが
- 性器腫瘍、男性
- 泌尿生殖器腫瘍
- 部位別新生物
- 新生物
- 生殖器疾患、男性
- 前立腺疾患
- 男性の泌尿生殖器疾患
- 化学誘発性疾患
- 中毒
- 前立腺腫瘍
- 咬傷と刺傷
- 抗悪性腫瘍剤、免疫
- 抗悪性腫瘍剤
- 薬理作用の分子機構
- ペプチド
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 薬理学的行動
- 化学作用と用途
- 治療用途
- 酵素
- 酵素と補酵素
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 受容体、細胞表面
- 膜タンパク質
- 酸化還元酵素
- 免疫グロブリンFCフラグメント
- 免疫グロブリン断片
- ペプチドフラグメント
- 免疫グロブリン定数領域
- 受容体、腫瘍壊死因子
- 受容体、サイトカイン
- 受容体、免疫学的
- シトクロム
- 混合機能オキシゲナーゼ
- オキシゲナーゼ
- ヘメプロテン
- エタネルセプト
- 免疫チェックポイント阻害剤
- ペンブロリズマブ
- シトクロムP-450酵素システム
その他の研究ID番号
- 20180101
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD 共有時間枠
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD 共有アクセス基準
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。